Boehringer Ingelheim Targets 25 New Treatments by 2030

German pharmaceutical firm Boehringer Ingelheim has outlined a bold strategy to introduce 25 innovative treatments by the year 2030. This initiative is part of their 2023 financial report, where they have also outlined plans to initiate 10 new clinical trials in the next 12 to 18 months.

The company's late-stage research is gaining momentum, especially in the fields of oncology, mental health, cardiovascular, renal, and metabolic diseases. In 2023, the FDA recognized their efforts by granting them five fast-track designations and one breakthrough therapy designation.

Boehringer has highlighted several promising drug candidates. One of these is Brigimadlin, an MDM2-p53 agonist, which has advanced to a pivotal trial for treating dedifferentiated liposarcoma. Another is zongertinib, an investigational HER2 tyrosine kinase inhibitor, whose development has been expedited following positive initial findings.

In 2024, Boehringer's candidate survodutide for treating metabolic dysfunction-associated steatohepatitis showed significant promise, with 83% of patients experiencing an improvement in liver disease without fibrosis progression. This candidate is now entering Phase III trials for obesity.

Hubertus von Baumbach, the chairman of Boehringer Ingelheim's board of managing directors, expressed his enthusiasm for the company's balanced and robust pipeline. He emphasized the company's commitment to accelerating the development of new treatments and making them accessible to patients as quickly and efficiently as possible. The aim is to improve healthcare systems and make them more equitable.

Despite the optimistic outlook, the company has faced challenges with the sales of its Humira biosimilar, Cyltezo, in the U.S. market. Slow sales have led to staff reductions, as AbbVie has managed to stave off competition from biosimilars for now.

However, Boehringer reported a 9.7% increase in net sales for 2023, driven by the sales of Jardiance, a treatment for diabetes and heart failure, and Ofev, a treatment for pulmonary fibrosis. The company's 2023 group net sales reached €25.6 billion, with a 10.3% growth in the human pharmaceutical sector. Jardiance sales increased by 31% to €7.4 billion, while Ofev sales rose by 12.8% to €3.5 billion.

Boehringer Ingelheim's ambitious pipeline and financial growth underscore the company's dedication to advancing healthcare and addressing unmet medical needs.